Please type a plus sign (+) inside this box → [+]

PTO/SB/21 (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/895,463
Filing Date	June 29, 2001
First Named Inventor	A.K. Gunnar Aberg
Group Art Unit	2122
Examiner Name	
Total Number of Pages in This Submission	
Attorney Docket Number	559P019

ENCLOSURES *(check all that apply)*

- [ ] Fee Transmittal Form
  - [ ] Fee Attached
- [ ] Amendment / Reply
  - [ ] After Final
  - [ ] Affidavits/declaration(s)
- [ ] Extension of Time Request
- [ ] Express Abandonment Request
- [X] Information Disclosure Statement
- [ ] Certified Copy of Priority Document(s)
- [ ] Response to Missing Parts/ Incomplete Application
  - [ ] Response to Missing Parts under 37 CFR 1.52 or 1.53
- [ ] Assignment Papers *(for an Application)*
- [ ] Drawing(s)
- [ ] Licensing-related Papers
- [ ] Petition
- [ ] Petition to Convert to a Provisional Application
- [ ] Power of Attorney, Revocation Change of Correspondence Address
- [ ] Terminal Disclaimer
- [ ] Request for Refund
- [ ] CD, Number of CD(s) _____
- [ ] After Allowance Communication to Group
- [ ] Appeal Communication to Board of Appeals and Interferences
- [ ] Appeal Communication to Group *(Appeal Notice, Brief, Reply Brief)*
- [ ] Proprietary Information
- [ ] Status Letter
- [X] Other Enclosure(s) *(please identify below)*:
  18- References

Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm *or* Individual name	Kevin S. Lemack Nields & Lemack
Signature	
Date	September 14, 2001

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date: Sept. 14, 2001

Typed or printed name	Kevin S. Lemack		
Signature		Date	September 14, 2001

IN THE UNITE STATES PATENT AND TRADEMAR OFFICE

Applicant	:	A.K. Gunnar Aberg
Serial No.	:	09/895,463
Filed	:	June 29, 2001
For	:	TOLTERODINE METABOLITES
Examiner	:	Not yet assigned
Art Unit	:	2122
Attorney Docket No.	:	559P019

Assistant Commissioner of Patents and Trademarks
Washington, D.C. 20231

Sir:

INFORMATION DISCLOSURE STATEMENT

The Examiner is respectfully requested to consider the enclosed documents which are listed on the attached form PTO 1449.

Copies of the documents listed on the attached form are filed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington D.C. 20231, on **September 14, 2001**

Signature: **Kevin S. Lemack**
Date: **September 14, 2001**

Respectfully submitted,

Kevin S. Lemack
Attorney for Applicants
Registration No. 32,579
Nields & Lemack
176 E. Main Street
Westboro, MA 01581
TEL: (508) 898-1818

FORM PTO-1449

ATTY. DOCKET NO.	SERIAL NO.
559P019	09/895,463
A.K. Gunnar Aberg	
FILING DATE	GROUP
June 29, 2001	2122

LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

REFERENCE DESIGNATION **U.S. PATENT DOCUMENTS**

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	5,236,956	8/1993	Sjogren et al.	514	617	
	AB	5,382,600	1/1995	Jonsson et al.	514	603	
	AC	5,532,278	7/1996	Aberg et al.	514	617	
	AD	5,559,269	9/1996	Johansson et al.	564	443	
	AE	5,677,346	10/1997	Aberg et al.	51	617	
	AF	5,686,464	11/1997	Johansson et al.	514	315	
	AG	5,736,577	4/1998	Aberg et al.	514	617	
	AH	5,922,914	7/1999	Gage et al.	564	413	
	AI						
	AJ						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	BA	0 325 571	7/1989	Europe				
	BB	0 667 852	8/1995	Europe				

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

_____ CA

(1) Nilvebrant et al.: Tolterodine - a new bladder-selective antimuscarinic agent. Europ. J. Pharmacol. 1997, 327: 196-207
--- There are over 20,000 publications on the drug tolterodine. This publication by Nilvebrant et al. is one of the more comprehensive reviews of the pharmacological activities of tolterodine, written by the people that invented tolterodine.

_____ CB

(2) Nilvebrant et al.: Antimuscarinic potency and bladder selectivity of PNU-200577, a major metabolite of tolterodine. Pharmacol Toxicol, 1997, 81:169-172
--- Describes 5-hydroxymethyl-tolterodine as a major metabolite of tolterodine

_____ CC

(3) Brynne et al.: Pharmacokinetics and pharmacodynamics of tolterodine in man: a new drug for the treatment of urinary bladder overactivity. Int J Clin Pharmacol Ther 1997, 35: 287-295
--- Demonstrates that tolterodine undergoes extensive and variable hepatic first-pass metabolism. Both N-dealkylation and oxidation of of the 5-methyl group are mentioned (see page 293, Discussion)

_____ CD

(4) Andersson et al.: Biotransformation of tolterodine, a new muscarinic antagonist, in mice, rats, and dogs. Drug Metab Dispos. 1998, 26:528-535
---The in vivo metabolism of tolterodine in mice, rats and dogs is described. Both dealkylated and 5-HM-oxidized metabolites are described

(5) Gillberg, P-G, Sundquist, S.: Pharmacological profile of DDO1 and desethyloxybutynin (DEOB). J. Urol 1997, 157: 81 p (Abstract)
_____ CE --- This publication concerns the antimuscarinic activity of the tolterodine metabolite 5-hydroxymethyl-tolterodine (here called DDO1) and an active metabolite of the competing drug oxybutynin (desethyl-oxybutynin, here called DEOB)

(6) Pharmacia-Upjohn: Prescribing Information for Detrol (tolterodine tablets) http://www.detrol.com.pi/index.htm
_____ CF --- This is the official drug product information from the manufacturer. The metabolism of tolterodine is described on pages 1 and 2. On page 6 there is a discussion of the risk for QT prolongation. A prolongation of 10 - 20% in the dog is called a "slight prolongation" although it is well known that a prolongation of 25 - 30% is fatal.

(7) Postlind et al.: Tolterodine, a new muscarinic receptor antagonist, is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos 1998, 26: 289-293).
_____ CG --- This publication describes how the metabolites of tolterodine (by specific liver enzymes). Both the formation of 5-hydroxymethyl-tolterodine and the secondary amine metabolite are described in detail.

(8) Stahl et al.: Urodynamic and other effects 0f Tolterodine... Neurourol Urodyn 1995, 14: 647-655
_____ CH --- This publication deals with clinical pharmacological activities and is part of the core documentation for tolterodine,

EXAMINER	DATE CONSIDERED
EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance *and* not considered. Include copy of this form with next communication to applicant.	

*=English Abstract

SR=Cited in Search Report